ArticleCell communication and signaling : CCS2026
The Galectin-3-binding protein promotes angiogenesis in pancreatic cancer via simultaneous upregulation of VEGFA and direct HUVEC activation mediated by and VAMP5-STAT3.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is ranked by the lowest 5-year survival rate worldwide. Given the lack of early symptoms and diagnostic biomarkers, most patients present with either local or distant metastasis at diagnosis. We previously demonstrated that Galectin-3-binding protein (Gal-3BP) is overexpressed in PDAC cells and promotes metastasis through the EGFR pathway, using proteomic analysis of PDAC tumor interstitial fluid (TIF). In the present study, we show the Gal-3BP promotes angiogenesis in PDAC by vascular endothelial growth factor A (VEGFA) upregulation via STAT3 activation. Furthermore, we reveal the Gal-3BP directly promotes migration and tube formation of vascular endothelial cells through STAT3 phosphorylation, mediated not by a VEGF receptor but by VAMP5. To explore the clinical application of these findings, we developed a humanized, high-affinity Gal-3BP antibody to block the dual angiogenic function of Gal-3BP. The #132 clone of the Gal-3BP antibody significantly reduced blood vessel density in PDAC orthotopic tumors and attenuated PDAC metastasis in a lung metastasis model. Therefore, we demonstrate the antibody-mediated blockade of Gal-3BP attenuates the angiogenesis in PDAC and propose it as a novel therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.